Ibogaine and Noribogaine in the Treatment of Drug Dependency: A State of the Art Review about Safety and Efficacy
Outcomes Syst. review moderate
AI-extracted · unverified · confirm at source
MSc dissertation systematic review (2000-2020): ibogaine/noribogaine safety and efficacy in substance use disorders. Confirms anti-addictive properties, cardiac risks, need for medical supervision.
Dosing: 7.40–55 mg/kg ibogaine HCl (mean 21.7 mg/kg; Noller 55 mg/kg was cumulative over 24–96h); noribogaine 60–180 mg (oral)
Sample size: 193
Safety data present: QTC
Contraindications: Past medical history of epilepsy, History of stroke, Axis I psychotic disorders, Significant cardiovascular conditions, Hepatic or renal impairment, Hypertension or hypotension, Endocrine disorders, Motor neurone disease